Healthcare
3i exits Asian medical device maker LHi to US trade buyer
3i Group has exited LHi Technology – a medical equipment manufacturer bought from Baring Private Equity Asia in 2008 – to US-based Carlisle Companies for an enterprise valuation of around $195 million, claiming a 2.9x money multiple.
CVC-owned SPi to sell US healthcare business for $235m
SPi Global, a Philippines-based business process outsourcing (BPO) provider owned by CVC Capital Partners, has agreed to sell its US healthcare business to Conifer Health Solutions in a deal worth $235 million.
Singapore supports med-tech accelerator program
Spring Seeds Capital, an investment arm of government-backed Spring Singapore, has launched an initiative that could channel up to S$60 million ($47 million) into local medical technology start-ups.
Blackstone pins down China's Xinrong
Driven by an aging population, increasing health awareness and a rising middle class, China's medical device market is growing at a rapid pace. A recent report by the Hong Kong Medical and Healthcare Device Industries Association reveals that since 2000...
Blackstone in China orthopedics play
The Blackstone Group has picked up a significant stake in Chinese medical devices company Xinrong Best Medical Instrument. Financial details were not disclosed but the deal is understood to be worth around $100 million.
India Value Fund picks 10% stake in Biocon research unit
India Vaue Fund Advisors (IVFA) has bought a 10% stake in Syngene International, the research unit of Indian bio-pharmaceuticals firm Biocon, for INR3.8 billion ($62 million).
Xiaomi Ventures backs China health products maker
Xiaomi Ventures, a corporate VC unit of Chinese mobile phone maker Xiaomi, has paid $25 million for a 20% stake in iHealth, an offshore unit of healthcare electronics maker Andon Health.
Temasek wins approval to buy Intas stake from ChrysCapital
Temasek Holdings has received approval from the Competition Commission of India (CCI) to acquire a stake in Intas Pharmaceuticals from ChrysCapital Partners.
VCs back Zai Lab drug development model
Few VC firms are keen to invest in China's early-stage drug discovery space because the development cycle is long and risky. Taking a new drug from clinical testing to commercialization often takes 7-10 years and the success rate in China is less than...
China stem cell storage firm launches $813m M&A fund
Zhongyuan Union Stem Cell Bio-engineering, a Chinese stem cell storage service operator, has partnered with China Yinhong Capital to launch an industry M&A fund with a target of RMB5 billion ($813 million).
OrbiMed commits $15m to China's GC-Rise Pharma
OrbiMed has committed $15 million in Series B funding to GC-Rise Pharmaceutical, a Chinese healthcare services provider.
Tencent pumps $70m into China healthcare networking site
Tencent Holdings has invested $70 million into dxy.com, a Chinese networking and information-sharing site for healthcare professionals
China's Zai Lab raises $30m Series A round
Qiming Venture Partners has led a $30 million Series A round of funding for Zai Lab, a Shanghai-based biotech drug developer, with participation from KPCB, Sequoia Capital and TF Capital.
Hony raises $528m with another part exit from CSPC Pharma
Hony Capital has made its second partial exit from CSPC Pharmaceutical Group in three months, selling an 11% stake in the Hong Kong-listed Chinese generic drugs maker for HK$4.01 billion ($528 million).
CITIC PE exits Jialin Pharma via trade sale to Luye Pharma
CITIC Private Equity will exit a 10.26% stake in Beijing Jialin Pharmaceutical after Luye Pharma Group, a Chinese drug maker, agreed to buy a majority stake in its industry peer.
Advent supports Australia radiology merger
Advent Private Capital has created the fourth-largest radiology group in Australia by bringing together two independent diagnostics businesses, Lake Imaging and South Coast Radiology.
Sequoia invests $139m in Chinese medical equipment maker
Sequoia Capital has acquired a 7% stake in Jiangsu Yuyue Medical Equipment & Supply, a Chinese medical equipment manufacturer, for RMB856 million ($139 million).
CITIC PE scraps plans for Biosensors takeover
CITIC Private Equity has abandoned plans for a takeover of Singapore-listed Biosensors International, although it will remain an active investor in the medical device manufacturer.
Walden Riverwood leads $8m Series A for Japan's Atonarp
Walden Riverwood Ventures has led an $8 million Series A round of funding for Atonarp, a Japanese developer of chemical sensors.
Sabre leads $8m round for Indian dermatology specialist
Sabre Partners as led an $8 million Series B round of funding for Vyome Biosciences, an Indian bio-pharmaceutical company that specializes in dermatology.
Qualcomm backs India's Portea Medical
Qualcomm Ventures, the venture investment unit of US chip-maker Qualcomm, has invested in India's Portea Medical, a provider of in-home healthcare services. The financial details of the transaction were not disclosed.
Shares in PE-backed Healthscope climb 5.2% on ASX debut
Shares in Healthscope,the Australian hospital operator backed by TPG Capital and The Carlyle Group, rose 5.2% to A$2.21 at the end its first day of trading yesterday following the largest Australian IPO in four years.
TPG, Carlyle to price Healthscope IPO at upper-end of range - report
TPG Capital and The Carlyle Group are to price shares in Australian hospital chain Healthscope at A$2.10 a share - the upper-end of the target range, generating A$2.25 billion ($2.12 billion).
China's JD Capital launches medical, energy funds
JD Capital has launched three renminbi-denominated funds to invest in the medical and energy sectors.